Valuation: Sprint Bioscience AB

Market Cap 351M 36.95M 31.91M 29.99M 27.27M 51.27M 3.53B 52.12M 137M 1.77B 139M 136M 5.88B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 351M 36.95M 31.91M 29.99M 27.27M 51.27M 3.53B 52.12M 137M 1.77B 139M 136M 5.88B EV / Sales 2026 *
4.14x
EV / Sales 2027 * 2.27x
Free-Float
64.78%
Yield 2026 *
-
Yield 2027 * -
1 day-2.35%
1 week-4.86%
Current month-7.50%
1 month-9.02%
3 months-8.01%
6 months+53.46%
Current year+126.53%
1 week 3.23
Extreme 3.23
3.59
1 month 3.21
Extreme 3.21
3.8
Current year 1.36
Extreme 1.355
4.59
1 year 0.51
Extreme 0.512
4.59
3 years 0.36
Extreme 0.36
4.59
5 years 0.36
Extreme 0.36
5.55
10 years 0.36
Extreme 0.36
41.5
Manager TitleAgeSince
Chief Executive Officer 42 01/10/2023
Chief Tech/Sci/R&D Officer 55 01/01/2009
Director of Finance/CFO 55 04/05/2026
Director TitleAgeSince
Chairman 70 01/01/2010
Director/Board Member 50 01/01/2019
Chairman 58 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
-2.35%-4.86%+456.86%+568.67% 36.95M
-1.90%+2.85%+62.82%+104.13% 70.07B
-3.21%-4.32%+31.85%+57.27% 52.87B
-2.05%-5.61%-3.18%+449.71% 27.02B
-1.27%-1.57%+45.90%+8.25% 23.61B
+1.05%-0.62%-18.00%-11.93% 23.38B
+3.81%+20.97%+266.37%+531.28% 19.43B
+0.10%+1.40%+35.36%-19.94% 18.75B
-0.95%-3.52%+19.93%+594.00% 15.85B
+1.24%-5.23%+33.75%+137.66% 12.7B
Average -0.55%+1.72%+93.17%+241.91% 26.37B
Weighted average by Cap. -1.09%+0.55%+50.29%+165.05%

Financials

2026 *2027 *
Net sales 84.8M 8.92M 7.7M 7.24M 6.58M 12.37M 853M 12.58M 33.16M 427M 33.48M 32.75M 1.42B 155M 16.3M 14.08M 13.23M 12.03M 22.62M 1.56B 22.99M 60.6M 780M 61.2M 59.87M 2.59B
Net income - -
Net Debt - -
Logo Sprint Bioscience AB
Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
Employees
30
Date Price Change Volume
14/08/26 SEK 3.330 -2.35% 129,008
13/08/26 SEK 3.410 +5.57% 294,484
12/08/26 SEK 3.230 -3.87% 526,107
11/08/26 SEK 3.360 -2.33% 149,248
10/08/26 SEK 3.440 -1.71% 92,828

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRINT Stock